InPreSS | International Pregnancy Safety Study

Original description

This is a proposal for a global fellowship position within the International Pregnancy Safety Study (InPreSS), a recently established international collaboration based at the Centre for Pharmacoepidemiology, Karolinska Institute (CPE/KI), Sweden, between researchers in all five Nordic countries and the Harvard School of Public Health (HSPH), USA. The majority of pregnant women take prescription drugs but there is limited evidence of their efficacy and safety. InPreSS aims to conduct exceedingly important research into the risk and benefits of prescribed drug use during pregnancy. The overarching objective of this fellowship is to provide advanced training in reproductive pharmacoepidemiology while creating a platform from which to launch an independent academic career in the EU. Three specific aims are to: 1) investigate the efficacy/safety of prescribed drugs used treatment of diabetes during pregnancy; 2) to trial the InPreSS international research model to evaluate short- and long-term infant and maternal health outcomes following use of prescribed drugs for chronic disease treatment during pregnancy using an unparalleled global resources of over 5 million pregnancies; 3) provide experience and mentorship at HSPH to design and deliver courses in pharmacoepidemiology in Sweden. Aims will be achieved via an 18-month out-going phase at HSPH where the Fellow will use the latest methodologies in pharmacoepidemiology to analyze a dataset comprised of US health insurance data, and a 12-month return-phase at CPE/KI where the results will be combined using meta-regression techniques. The Fellow will receive the highest quality support while facilitating long-term partnerships, training the next generation of researchers, and contributing to the field with studies that will directly impact clinical practice and guidelines for pregnant women.

Status

CLOSED

Url

https://cordis.europa.eu/project/id/844728

Call topic

MSCA-IF-2018

Update Date

28-04-2024